🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/refractory High Grade B Cell Lymphoma

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites📍 Minneapolis📍 Columbus📍 Richmond Yazeed Sawalha · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site📍 Seattle University of Washington · Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Ther… Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites📍 Anchorage📍 Clovis📍 Fullerton Hoffmann-La Roche · Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites📍 Tucson📍 Tucson📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia NCT03418038Phase 24 sites📍 Mankato📍 Rochester📍 Eau Claire Mayo Clinic · Tests: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311Phase 1, Phase 25 sites📍 Sacramento📍 Cleveland📍 Portland Estrella Immunopharma, Inc. · Tests: EB103 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites📍 Duarte📍 Chicago📍 New York AIDS Malignancy Consortium · Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine Study of CAR-T Therapy in Older Patients NCT04300998n/a1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go, Cognition, Geriatric Depressio… NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites📍 Ankara📍 Ankara📍 Ankara Health Institutes of Turkey · Tests: Talikabtagene Autoleucel Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment NCT05890352Phase 2104 sites📍 Tucson📍 Tucson📍 Beverly Hills SWOG Cancer Research Network · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells NCT07042438Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy, Fecal Microbiota Transplantation, Leukapheresis Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites📍 Duarte📍 Sacramento📍 Tampa National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma NCT05755087Phase 11 site📍 Columbus Lapo Alinari · Tests: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Tegavivint, Bone Marrow Biopsy A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 Immunotherapy in Lymphoma NCT06796517n/a2 sites📍 Seoul📍 Seoul Sung-Soo Park · Tests: CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody, Proteasome Inhibitor Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies NCT05418088Phase 12 sites📍 Columbus📍 Columbus Sumithira Vasu · Tests: Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07365306Phase 23 sites📍 Duarte📍 Newnan📍 Zion City of Hope Medical Center · Tests: Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, B… A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies NCT06703892Phase 11 site📍 Taipei GenomeFrontier Therapeutics TW Co., Ltd. · Tests: GF-CART01, GF-CART01, GF-CART01 Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients NCT07473167Phase 1, Phase 21 site📍 Seoul TICAROS Co., Ltd. · Tests: TC011 Epcoritamab-CAR T Cells for Large B-cell Lymphomas NCT06458439Phase 21 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Epcoritamab Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT05672251Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Loncastuximab Tesirine, Mosunetuzumab Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) NCT07225439Phase 12 sites📍 Cleveland📍 Cleveland Paolo Caimi, MD · Tests: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319Phase 11 site📍 Boston Marcela V. Maus, M.D.,Ph.D. · Tests: CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735Phase 17 sites📍 Calgary📍 Calgary📍 Vancouver British Columbia Cancer Agency · Tests: CLIC-2201 Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU NCT06116110n/a11 sites📍 Gilbert📍 Stanford📍 New Haven Miltenyi Biomedicine GmbH · Tests: Long-term Follow-Up Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients NCT04836507Phase 1, Phase 22 sites📍 Seoul📍 Seoul Curocell Inc. · Tests: CRC01, Fludarabine, Cyclophosphamide Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure NCT06918912Phase 27 sites📍 Alessandria📍 Bologna📍 Cuneo Istituto Clinico Humanitas · Tests: Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy